

Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims.

Listing of Claims

1-30. (Canceled)

31. (Currently Amended) A method of treating Sjögren's Syndrome comprising, administering an effective amount of an agonistic anti-TR17 antibody or fragment thereof to a patient in need thereof wherein said anti-TR17 antibody or fragment thereof specifically binds a TR17 protein expressed on the surface of a cell wherein said TR17 protein is encoded by a polynucleotide that encodes amino acids 1 to 293 of SEQ ID NO:2 and wherein said anti-TR17 antibody inhibits B cell proliferation or immunoglobulin production.

32-35. (Canceled)

36. (Currently Amended) A method of inhibiting B cell proliferation, comprising contacting a B cell with an effective amount of an agonistic anti-TR17 antibody or fragment thereof, wherein said anti-TR17 antibody or fragment thereof specifically binds a TR17 protein expressed on the surface of a cell wherein said TR17 protein is encoded by a polynucleotide that encodes amino acids 1 to 293 of SEQ ID NO:2 and wherein said anti-TR17 antibody inhibits B cell proliferation.

37. (Canceled)

38. (Currently Amended) A method of inhibiting immunoglobulin production, comprising contacting a B cell with an effective amount of an agonistic anti-TR17 antibody or fragment thereof, wherein said anti-TR17 antibody or fragment thereof specifically binds a TR17 protein expressed on the surface of a cell wherein said TR17 protein is encoded by a polynucleotide that encodes amino acids 1 to 293 of SEQ ID NO:2 and wherein said anti-TR17 antibody inhibits immunoglobulin production.

39-63. (Cancelled)

64. (Withdrawn) The method of claim 31 wherein said antibody or fragment thereof is a monoclonal antibody.

65. (Withdrawn) The method of claim 31 wherein said antibody or fragment thereof is a polyclonal antibody.

66. (Currently Amended) The method ~~antibody or fragment thereof~~ of claim 31 wherein said antibody or fragment thereof is selected from the group consisting of:

- (a) a chimeric antibody;
- (b) a humanized antibody;
- (c) a human antibody;
- (d) a single chain antibody; and
- (e) a Fab fragment.

67. (Withdrawn) The method of claim 31 wherein said antibody or fragment thereof is conjugated to a cytotoxin.

68. (Withdrawn) The method of claim 36 wherein said antibody or fragment thereof is a monoclonal antibody.

69. (Withdrawn) The method of claim 36 wherein said antibody or fragment thereof is a polyclonal antibody.

70. (Currently Amended) The method ~~antibody or fragment thereof~~ of claim 36 wherein said antibody or fragment thereof is selected from the group consisting of:

- (a) a chimeric antibody;
- (b) a humanized antibody;
- (c) a human antibody;
- (d) a single chain antibody; and
- (e) a Fab fragment.

71. (Withdrawn) The method of claim 36 wherein said antibody or fragment thereof is conjugated to a cytotoxin.

72. (Withdrawn) The method of claim 38 wherein said antibody or fragment thereof is a monoclonal antibody.

73. (Withdrawn) The method of claim 38 wherein said antibody or fragment thereof is a polyclonal antibody.

74. (Currently Amended) The method ~~antibody or fragment thereof~~ of claim 38 wherein said antibody or fragment thereof is selected from the group consisting of:

- (a) a chimeric antibody;
- (b) a humanized antibody;
- (c) a human antibody;
- (d) a single chain antibody; and
- (e) a Fab fragment.

75. (Withdrawn) The method of claim 38 wherein said antibody or fragment thereof is conjugated to a cytotoxin.

76. (Previously Presented) The method of claim 36 which is *in vitro*.

77. (Previously Presented) The method of claim 38 which is *in vitro*.